Compare PLBY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | CHRS |
|---|---|---|
| Founded | 1953 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.4M | 209.8M |
| IPO Year | 2020 | 2014 |
| Metric | PLBY | CHRS |
|---|---|---|
| Price | $1.18 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $5.51 |
| AVG Volume (30 Days) | ★ 990.7K | 966.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 87.50 | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,928,000.00 | N/A |
| Revenue This Year | $9.17 | $73.08 |
| Revenue Next Year | $7.10 | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $1.19 | $0.80 |
| 52 Week High | $2.75 | $2.62 |
| Indicator | PLBY | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 62.68 |
| Support Level | N/A | $1.55 |
| Resistance Level | $1.94 | $1.79 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 2.33 | 89.47 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.